Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Seattle, Washington
- Most recent report
- 8-K, filed Oct 9, 2026
- Incorporated
- Delaware
- Filings on record
- 641 filings
- On EDGAR
- CIK 1488039
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Smaller reporting company
Financials 8 of 63
News 8 of 176
- 8-K Significant contract Oct 9, 2026
- 8-K Other events Sep 29, 2026
- 8-K Current report on a material event Sep 18, 2026
- 8-K Quarterly results Aug 7, 2026
- 8-K Significant contract Jun 11, 2026
- 8-K Current report on a material event May 8, 2026
- 8-K Shareholder vote results May 8, 2026
- 8-K Other events Apr 16, 2026
Prospectuses and Registrations 8 of 86
- 424B5 Prospectus supplement for an offering Jun 12, 2026
- 424B5 Prospectus supplement for an offering Feb 20, 2026
- 424B3 Prospectus supplement for an offering Feb 20, 2026
- S-8 Registration statement for an employee plan Mar 26, 2025
- 424B5 Prospectus supplement for an offering Nov 19, 2024
- S-3 Shelf registration statement May 13, 2024
- S-3 Shelf registration statement Apr 21, 2021
- S-8 Registration statement for an employee plan Mar 31, 2021
Proxies 8 of 29
- DEF 14A Proxy statement for a shareholder vote Mar 30, 2026
- PRE 14A Preliminary proxy statement Mar 20, 2026
- DEF 14A Proxy statement for a shareholder vote Dec 22, 2025
- PRE 14A Preliminary proxy statement Dec 12, 2025
- DEF 14A Proxy statement for a shareholder vote Mar 26, 2025
- DEF 14A Proxy statement for a shareholder vote May 23, 2024
- PRE 14A Preliminary proxy statement May 10, 2024
- DEFA14A Extra proxy material Apr 26, 2023
Ownership 8 of 190
- 4 Insider reported a trade May 14, 2026
- 4 Insider reported a trade May 14, 2026
- 4 Insider reported a trade May 14, 2026
- 4 Insider reported a trade May 14, 2026
- 4 Insider reported a trade May 14, 2026
- 4 Insider reported a trade May 14, 2026
- 4 Insider reported a trade Mar 31, 2026
- 4 Insider reported a trade Mar 30, 2026
Other 8 of 97
- ARS Annual report sent to shareholders Mar 30, 2026
- ARS Annual report sent to shareholders Mar 26, 2025
- EFFECT Notice that a registration became effective May 23, 2024
- CORRESP Reply to SEC staff May 21, 2024
- UPLOAD Comment letter from SEC staff May 21, 2024
- DEL AM May 14, 2024
- ARS Annual report sent to shareholders May 10, 2024
- ARS Annual report sent to shareholders Mar 30, 2023
Everything here comes from Atossa Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.